Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021)

Mesoblast (MESO) posted Non-Current Deferred Tax Liability of $80.2 million for Q4 2021, little changed sequentially from $80.2 million in Q3 2021, and little changed YoY from $80.1 million in Q4 2020.

Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends

Mesoblast has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $80.2 million in Q4 2021.

  • Quarterly Non-Current Deferred Tax Liability changed 0.11% year-over-year to $80.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $80.2 million (changed 0.11% YoY) and the FY2021 annual result came in at $80.2 million, up 10881.37% from the prior year.
  • Non-Current Deferred Tax Liability was little changed at $80.2 million in Q4 2021 per MESO's latest filing, from $80.2 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $80.2 million in Q3 2021 and troughed at $730000.0 in Q2 2020.
  • A 5-year average of $45.0 million and a median of $47.8 million in 2017 frame the typical range for Non-Current Deferred Tax Liability.
  • The sharpest annual moves came in 2020 and 2021: Non-Current Deferred Tax Liability plunged 99.05% in 2020, then soared 10881.37% in 2021.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $23.9 million in 2017, then tumbled by 30.98% to $16.5 million in 2018, then plunged by 58.06% to $6.9 million in 2019, then soared by 1057.43% to $80.1 million in 2020, then grew by 0.11% to $80.2 million in 2021.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $80.2 million, $80.2 million, and $80.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Mesoblast 2.01 Bn 1.87 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2021 80.21 Mn
Dec 31, 2021 80.21 Mn
Sep 30, 2021 80.25 Mn
Sep 30, 2021 80.25 Mn
Jun 30, 2021 80.16 Mn
Jun 30, 2021 80.16 Mn
Mar 31, 2021 80.20 Mn
Mar 31, 2021 80.20 Mn
Dec 31, 2020 80.12 Mn
Dec 31, 2020 80.12 Mn
Sep 30, 2020 79.91 Mn
Sep 30, 2020 79.91 Mn
Jun 30, 2020 730,000.00
Jun 30, 2020 730,000.00
Mar 31, 2020 4.97 Mn
Mar 31, 2020 4.97 Mn
Dec 31, 2019 6.92 Mn
Dec 31, 2019 6.92 Mn
Sep 30, 2019 9.20 Mn
Sep 30, 2019 9.20 Mn